Specific crRNA, system and method for identifying different types of ASFV based on CRISPR / Cas12a
Through the detection method combined with CRISPR/Cas12a technology and isothermal amplification, the problem of complex detection of African swine fever virus and high false positives is solved, and rapid and accurate detection of African swine fever virus, especially wild virus strains and gene deletion strains are achieved. The distinction between the two groups meets the fast, specific and sensitive detection needs.
Patent Information
- Application Number
- CN202411240547.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-15
AI Technical Summary
In the prior art, the detection of African swine fever virus is complex, and the detection results are highly false positive, and it is impossible to quickly distinguish African swine fever wild strains from gene deletion strains, which cannot meet the needs of rapid, specific and sensitive detection.
Using CRISPR/Cas12a-based specific crRNA and detection system, combined with isothermal amplification technology, the Cas12a protein and specific crRNA are used to recognize the ASFV target sequence, and the single-strand DNA cleavage and fluorescence or colloidal gold detection can achieve rapid, high specificity and high sensitivity. detection.
It realizes rapid, accurate and simple detection of African swine fever virus, reduces detection costs, avoids false positives, and can effectively distinguish between wild virus strains and gene deletion strains, which is suitable for on-site applications.
Smart Images

Figure CN118957154A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of animal pathogen molecular diagnosis, and specifically to specific crRNA, systems and methods for identifying different types of ASFV based on CRISPR / Cas12a. Background Art
[0002] African swine fever (ASF) is a highly contagious disease of pigs, which has caused huge economic losses to the pig industry due to its high mortality rate and rapid spread. Its pathogen is African swine fever virus (ASFV), which is a large double-stranded DNA virus. Due to the lack of vaccines and effective treatments for ASFV, disease control mainly relies on culling pigs. Existing ASFV detection methods recommended by the World Organization for Animal Health (OIE) rely on virus isolation, antigen measurement by fluorescent antibody test (FAT) or detection of viral genome by polymerase chain reaction (PCR). Although virus isolation is the gold standard for diagnosing ASFV, this time-consuming and complicated procedure is not suitable for real-time monitoring of the disease. Detection of ASFV antigens enables large-scale testing of samples, but is not sensitive enough to detect early infection. Both quantitative PCR (qPCR) and conventional PCR are rapid and sensitive methods for detecting ASFV. However, the PCR method requires skilled operation and a thermal cycler, which makes it less suitable for field applications. Isothermal amplification allows easier operation and rapid amplification of DNA at a constant temperature without relying on laboratory instruments. However, nonspecific DNA amplification and high false-positive rates remain a major problem.
[0003] Furthermore, African swine fever was introduced into my country in August 2018, and the first outbreak occurred in Liaoning, and then spread to many provinces in my country. Due to the long-term prevalence of African swine fever in my country, natural mutations or weakening of the virus due to gene deletions occurred, and some genes, especially envelope protein CD2v protein, and some genes of MGF360 or MGF505 multigene family were lost, which made the African swine fever epidemic in my country more complicated.
[0004] Therefore, there is an urgent need for a specific, sensitive, rapid, and instrument-free detection method to monitor ASFV and to identify wild-type African swine fever strains and gene-deficient vaccine strains. Summary of the invention
[0005] In view of the above-mentioned prior art, the purpose of the present invention is to address the problems in the prior art that African swine fever virus detection is complex, the detection results have a high false positive rate, and wild strains and gene-deficient strains cannot be quickly distinguished. Thereby, a specific crRNA, system and method for identifying different types of ASFV based on CRISPR / Cas12a is provided, which has high sensitivity, strong specificity, rapid visualization, and can effectively identify African swine fever wild strains and gene-deficient vaccine strains.
[0006] In order to achieve the above object, the present invention provides a specific crRNA for identifying different types of ASFV based on CRISPR / Cas12a, wherein the specific crRNA includes a first crRNA and a second crRNA; wherein,
[0007] The first crRNA is shown in SEQ ID No: 1 and / or SEQ ID No: 2;
[0008] The second crRNA is shown in one or more of SEQ ID No:3, SEQ ID No:4, SEQ ID No:5 and SEQ ID No:6.
[0009] Preferably, the first crRNA is as described in SEQ ID No: 2;
[0010] The second crRNA is shown in SEQ ID No:4 and / or SEQ ID No:6.
[0011] The present invention also provides a detection system for identifying different types of ASFV based on CRISPR / Cas12a, wherein the detection system comprises at least the specific crRNA as described above, a first isothermal amplification primer pair for amplifying the template to be tested and matched with the first crRNA, a second isothermal amplification primer pair for amplifying the template to be tested and matched with the second crRNA, and a ssDNA reporter system.
[0012] Preferably, the first isothermal amplification primer pair is selected from the first primer pair shown in SEQ ID No: 7 and SEQ ID No: 8 and / or the second primer pair shown in SEQ ID No: 9 and SEQ ID No: 10, and the second isothermal amplification primer pair is selected from the third primer pair shown in SEQ ID No: 11 and SEQ ID No: 12, the fourth primer pair shown in SEQ ID No: 13 and SEQ ID No: 14, the fifth primer pair shown in SEQ ID No: 15 and SEQ ID No: 16, and the sixth primer pair shown in SEQ ID No: 17 and SEQ ID No: 18. One or more.
[0013] Preferably, when containing the second crRNA as shown in SEQ ID No: 3 and / or SEQ ID No: 4, a third primer pair and / or a fourth primer pair is used;
[0014] When containing the second crRNA as shown in SEQ ID No: 5 and / or SEQ ID No: 6, the fifth primer pair and / or the sixth primer pair are used.
[0015] Preferably, the first isothermal amplification primer pair is selected from the second primer pair, and the second isothermal amplification primer pair is selected from the fourth primer pair and / or the sixth primer pair.
[0016] Preferably, the ssDNA reporter system comprises a first ssDNA reporter molecule for fluorescence detection, and / or a second ssDNA reporter molecule for colloidal gold detection;
[0017] Preferably, the nucleotide sequence of the first ssDNA reporter molecule is: 5'-TTTTTTTT-3', and the nucleotide sequence of the second ssDNA reporter molecule is: 5'-TTTATTT-3'.
[0018] Preferably, the 5' end of the first ssDNA reporter molecule is modified with a FAM group, and the 3' end is modified with a BHQ1 group;
[0019] The 5' end of the second ssDNA reporter molecule is modified with a FAM group, and the 3' end is modified with a Biotin group.
[0020] Preferably, the detection system further comprises a solubilizer and an activator required for the ERA process, and a Cas12a protein required for the CRISPR / Cas12a system; and,
[0021] Relative to 1pmol of Cas12a protein, the content of crRNA is 1-2pmol.
[0022] Preferably, the reaction conditions of the ERA process are: reaction at 37° C. for 20-30 min.
[0023] The present invention also provides an application of the specific crRNA described above, or the detection system described above, in the preparation of different types of ASFV identification detection kits.
[0024] The present invention also provides a method for identifying different types of ASFV for non-disease diagnosis purposes, and the identification method adopts the detection system described above.
[0025] Preferably, the identification method is used to identify at least two of the ASFV wild strain, the H240R deletion vaccine strain and the MGF505-7R deletion vaccine strain.
[0026] Preferably, the identification method comprises:
[0027] S100, releasing the nucleic acid in the sample to be tested to obtain a template to be tested, and using multiple sets of isothermal amplification primers to specifically amplify each template to be tested to obtain multiple corresponding amplification products;
[0028] S200, activating the non-specific single-stranded DNA cleavage activity of the Cas12a enzyme by binding crRNA to the specific gene sequence in the amplified product in step S100;
[0029] S300, based on the ssDNA reporter system, the plant type of the template to be tested is determined by detecting the reporter signal.
[0030] Preferably, when the ssDNA reporter system in step S300 uses the first ssDNA reporter molecule, the detection conditions are: using excitation light with a wavelength of 492 nm and detecting the radiated fluorescence intensity at a wavelength of 522 nm.
[0031] Compared with the prior art, the present invention has the following beneficial effects:
[0032] (1) The recognition and combination of crRNA designed by the present invention and ASFV target sequence are highly specific, and compared with traditional detection methods, this detection method effectively guarantees the accuracy of the detection results. The designed crRNA is not limited by the PAM sequence and can only specifically identify and shear single-stranded DNA, but cannot shear double-stranded DNA. Therefore, in the present invention, Cas12a protein does not consume the template for amplification, and amplification and Cas12a-crRNA detection can be carried out simultaneously in the same system, achieving high sensitivity.
[0033] (2) The present invention only needs 60 minutes at room temperature to read the test results through the color development of the test strip or the fluorescence intensity. The detection time is short and no expensive and complicated temperature control instrument is required. Only a constant temperature device and a fluorescence detection device are needed to complete the detection reaction, and the detection cost is low.
[0034] (3) The present invention uses CRISPR / Cas12a to cut specific sequences and immune flow chromatography technology to achieve rapid, highly specific, highly sensitive and visual detection of African swine fever virus nucleic acid. At the same time, based on the proposed amplification primers and crRNA for different gene-deficient strains, the differential detection of wild strains and gene-deficient strains of African swine fever virus is achieved. It provides an accurate, rapid and simple detection and identification method for clinical diagnosis and laboratory research. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the following specific embodiments, they are used to explain the present invention but do not constitute a limitation of the present invention. In the accompanying drawings:
[0036] Figure 1 This is a schematic diagram of the detection principle of the present invention for identifying different types of ASFV based on ERA-CRISPR / Cas12a;
[0037] Figure 2 This is a schematic diagram of the fluorescence signal of the screening results of specific crRNA for identifying different types of ASFV based on ERA-CRISPR / Cas12a in Preparation Example 1 of the present invention;
[0038] Figure 3 This is a fluorescence result diagram of the sensitivity detection of different types of ASFV based on ERA-CRISPR / Cas12a in Verification Example 1 of the present invention;
[0039] Figure 4 This is a fluorescence result diagram of specific detection of different types of ASFV based on ERA-CRISPR / Cas12a in Verification Example 2 of the present invention. ;
[0040] Figure 5 This is a colloidal gold test strip result diagram of sensitivity detection for identifying different types of ASFV based on ERA-CRISPR / Cas12a in Verification Example 1 of the present invention;
[0041] Figure 6 This is a graph showing the colloidal gold test strip results for specific detection of different types of ASFV based on ERA-CRISPR / Cas12a in Verification Example 2 of the present invention. DETAILED DESCRIPTION
[0042] The specific embodiments of the present invention are described in detail below. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.
[0043] Specifically, the present invention provides a nucleic acid rapid detection system for wild strains of African swine fever virus and gene-deficient vaccine strains based on CRISPR / Cas12a and ERA method isothermal amplification. More specifically, the technical solution of the present invention targets the CP530R gene, the MGF505-7R gene and the H240R gene, thereby differentially detecting wild strains of African swine fever virus, H240R gene-deficient vaccine strains and MGF505-7R gene-deficient vaccine strains. The detection principle is as follows Figure 1 shown.
[0044] The specific detection process includes the following steps:
[0045] Step a: Viral nucleic acid extraction: Use the African swine fever virus DNA extraction kit to extract viral nucleic acid, and follow the following steps: (1) Centrifuge the test sample at 12000r / min for 5 minutes to extract the supernatant; (2) Add swine fever virus lysis solution to the supernatant, mix well and place at room temperature for 5 minutes; (3) Add an appropriate amount of protein removal solution, mix well and place in a centrifuge for 5 minutes; (4) Place the supernatant in an EP tube, add a mixed solution of isopropanol and glacial acetic acid, and mix well. (5) Assemble the column and the collection tube together, add the column to the mixed solution, centrifuge for 1 min or filter the liquid; (6) Add washing solution to the column, let it stand for 1 min and filter the liquid; (7) Add desalted solution to the column and centrifuge for 1 min; (8) Place the column in an EP tube and add elution solution to the center of the column filter membrane. After 1 min, centrifuge to obtain the nucleic acid solution. If you want to increase the concentration of the solution, you can elute it again. Store the obtained DNA gene at -20℃ and the RNA at -80℃.
[0046] Step b: Selection of optimal temperature and time: In order to find the optimal reaction temperature and time for African swine fever, the selected plasmid is used as a template and reacted for 30 minutes at different water bath temperatures to amplify the target fragment. The standard plasmid is then placed in the most appropriate temperature environment for a reaction time of 5 to 40 minutes. A sample is obtained every 5 minutes, and the most suitable reaction time is determined based on the amplification effect, thereby forming an African swine fever virus EPA detection method.
[0047] Step c: using isothermal amplification primers to amplify the nucleic acid in the sample to be tested, specifically adding the product obtained in step a (i.e., the DNA template to be tested) to the ERA isothermal amplification system using the first primer pair and the second primer pair (preferably the second primer pair) of the specific amplification primers corresponding to CP530R of the African swine fever virus, the third primer pair and the fourth primer pair (preferably the fourth primer pair) of the specific amplification primers corresponding to MGF505-7R, and the fifth primer pair and the sixth primer pair (preferably the sixth primer pair) of the specific amplification primers corresponding to the H240R gene, and reacting at 37° C. for 20-30 minutes to amplify each to obtain the corresponding specific product;
[0048] Step d: using the CRISPR / Cas12a detection system to cut the African swine fever virus nucleic acid, specifically adding the amplified product in step c to the corresponding CRISPR / Cas12a detection system and reacting at 37°C for 30 minutes;
[0049] Step e: Use a fluorescent microplate reader or an immune colloidal gold test strip to detect the strain of African swine fever virus in the sample.
[0050] According to the above specific detection process, the detection system at least includes: CP530R gene for wild strains of African swine fever virus, MGF505-7R gene and H240R gene specific crRNA of the gene-deficient vaccine strain of African swine fever virus, CRISPR / Cas12a protein and single-stranded DNA (ssDNA) reporting system. It should be noted that, based on the selection in actual operation, one or two of the MGF505-7R gene-deficient vaccine strain and the H240R gene-deficient vaccine strain can be selectively selected for detection, so the corresponding specific crRNA here can be selected one or two and selectively applied. That is, the specific crRNA of the CP530R gene must be included in the detection system, and the specific crRNA of the MGF505-7R gene and the H240R gene can be selected one or both. Accordingly, if one of them is selected, only the wild strain and the corresponding gene-deficient strain can be identified; if both are used, the wild strain, the MGF505-7R gene-deficient strain and the H240R gene-deficient strain can be identified accordingly.
[0051] It should be further explained that the above three detection systems for different genes are each operated independently. That is, if it is necessary to carry out targeted detection of the above three genes to the same sample to be tested, then after the sample to be tested extracts the DNA template to be tested (i.e. after step a ends), the DNA template to be tested is divided into three parts, and each DNA template to be tested is amplified using the specific amplification primer of the corresponding gene to obtain the amplified product of the corresponding gene, and then the amplified product is added to the CRISPR / Cas12a detection system containing the corresponding specific crRNA for detection. That is, if the first primer pair or the second primer pair is used in step c, the first crRNA is used in step d;If the third primer pair or the fourth primer pair is used in step c, the second crRNA as shown in SEQ ID No:3 or SEQ ID No:4 is used in step d;If the fifth primer pair or the sixth primer pair is used in step c, the second crRNA as shown in SEQ ID No:5 or SEQ ID No:6 is used in step d. Each test only targets a set of primer pairs and their corresponding crRNA, and the detection system operation is performed multiple times according to actual identification needs.
[0052] In the ERA constant temperature amplification system of step c, each 20 μL of the EPA constant temperature amplification system includes: 20 μL of a dissolving agent, 2.5 μL of a 10 μM upstream primer, 2.5 μL of a 10 μM downstream primer, 1 μL of RNase free water, and 2 μL of an activator.
[0053] In the CRISPR / Cas12a detection system of step d, each 20 μL CRISPR / Cas12a detection system includes: 3 μL of 10×Buffer, 1 μL of LbCas12a, 6 μL of crRNA, 6 μL of ssDNA fluorescent probe, 10 μL of ERA amplification product in step c, and 8 μL of RNase free water.
[0054] In step e, if an immunocolloidal gold test strip is used for detection, then on the basis of step c, the CRISPR / Cas12a detection system is diluted in a PBS buffer solution at a volume ratio of 1:5, the sample area of the test strip is immersed in the diluted sample, and the intensity of the detection band is read by naked eyes after incubation at room temperature for 5-10 minutes; or other lateral flow test strips are carried out according to the corresponding color development method. When using an immunocolloidal gold test strip for detection, 5′-FAM-TTTATTT-Biotin-3′ labeled with 6-carboxyfluorescein (6-FAM) and a fluorescence quencher (BHQ1) is used as the ssDNA reporter system.
[0055] The immunocolloidal gold test strip comprises a sample pad, a conjugation pad, a nitrocellulose membrane, a water-absorbing pad and a PVC backing; the sample pad, the conjugation pad, the nitrocellulose membrane and the water-absorbing pad are sequentially adhered to the PVC backing; the conjugation pad is coated with a conjugate of mouse anti-6-carboxyfluorescein antibody labeled with colloidal gold; the nitrocellulose membrane is respectively coated with a quality control line composed of streptavidin and a detection line composed of rabbit anti-mouse IgG antibody.
[0056] In step e, if the fluorescence detection is performed by using an ELISA instrument, any fluorescence detection device that can perform fluorescence excitation and detection on the FAM fluorescence channel can be used for detection. The detection conditions used for fluorescence detection are to use an excitation light wavelength of 492nm and a detection wavelength of 522nm for the emission fluorescence intensity. When fluorescence detection is used, 5′-FAM-TTTTTTTT-BHQ1-3′ labeled with 6-carboxyfluorescein (6-FAM) and biotin is used as the ssDNA reporter system.
[0057] The ERA-Cas12a detection principle is: the viral genome extracted from the sample is amplified by the ERA constant temperature amplification technology for the target gene. Afterwards, crRNA recognizes the target double-stranded DNA through base complementary pairing, and the three combine to form a crRNA / Cas12a / target DNA ternary complex. After the complex is formed, the trans-cleavage activity of the Cas12a protein is activated, and the single-stranded DNA in the shearing system begins to be indiscriminate. When the single-stranded DNA probe with a FAM fluorescent group at one end and a fluorescent quenching group at the other end in the system is cut off, the FAM group can emit green fluorescence visible to the naked eye under the excitation of 470nm LED blue light. If the detection system after the reaction has a luminescent phenomenon, it means that the target detection result is positive, otherwise it is negative.
[0058] When using an ELISA fluorescence detector, when the African swine fever virus gene is present in the CRISPR / Cas12a detection system, the nuclease activity of the CRISPR / Cas12a protein will be specifically activated under the mediation of the African swine fever virus-specific crRNA. The activated CRISPR / Cas12a protein will cut the ssDNA FQreporter (the ssDNAFQ reporter is ssDNA labeled with the first ssDNA reporter molecule) labeled with a fluorescent group and a quenching group, thereby releasing the activated fluorescent group, and the fluorescence reading can be detected using an ELISA reader. Correspondingly, when the African swine fever virus gene sequence is not present in the sample to be detected, the fluorescence reading is displayed as a base value.
[0059] When using the immune colloidal gold test strip for detection, after the sample to be tested after CRISPR / Cas12a cutting is added to the colloidal gold test strip, the mouse anti-6-FAM antibody labeled with colloidal gold will combine with the ssDNA reporter system labeled with 6-FAM, and the complex will move from the quality control line to the detection line along the liquid flow direction; the streptavidin on the quality control line saturates the capture of the ssDNA reporter system labeled with biotin, thereby displaying the band; when CRISPR / Cas12a detects the gene of the African swine fever virus, it will cut off the ssDNA reporter system labeled with 6-FAM and biotin, so that the ssDNA fragment labeled with 6-FAM will be captured by the detection line for color development; when CRISPR / Cas12a cannot detect the gene sequence of the African swine fever virus, it cannot cut off the ssDNA reporter system labeled with 6-FAM and biotin, so that the ssDNA fragment labeled with 6-FAM will not be captured by the detection line for color development.
[0060] The following is a detailed description in conjunction with a specific embodiment. In the present invention, the primers used are synthesized and provided by Nanjing Jinweizhi Biotechnology Co., Ltd., the crRNA and probes used are synthesized and provided by Guangzhou Aidi Gene Technology Co., Ltd., and primers and standard plasmids are synthesized by GENEWIZ (Jinweizhi) Biotechnology Co., Ltd. Cas12a protein is purchased from Guangzhou Aidi Gene Biotechnology Co., Ltd. LbCas12a (Guangzhou Aidi Gene Technology Co., Ltd., Article No. EDE0005-2000), basic nucleic acid amplification kit (ERA method) (Suzhou Xianda Gene Technology Co., Ltd., Article No. KS101), plasmid small extraction kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., Article No. DP103), enzyme-free sterile water (Beijing Solebold Technology Co., Ltd., Article No. R1600).
[0061] The viral genomic DNA used is obtained by extracting the commercially available attenuated or inactivated vaccine nucleic acid of the corresponding virus using a nucleic acid extraction kit and then storing it in the laboratory for future use. Specifically, the pseudorabies live vaccine (Bartha-K61 strain) is derived from the commercial product of China Animal Husbandry Co., Ltd., the porcine transmissible gastroenteritis and porcine epidemic diarrhea bivalent live vaccine is derived from the commercial product of Wuhan Keqian Biological Co., Ltd., the Lanjie porcine reproductive and respiratory syndrome live vaccine (R98 strain) is derived from the commercial product of China Animal Husbandry Co., Ltd., the Kexining porcine parvovirus inactivated vaccine is derived from the commercial product of Wuhan Keqian Biological Co., Ltd., the Kewening classical swine fever live vaccine (cell source) is derived from the commercial product of Wuhan Keqian Biological Co., Ltd., and the Keyuaning porcine circovirus type 2 inactivated vaccine is derived from the commercial product of Wuhan Keqian Biological Co., Ltd.
[0062] Preparation Example 1: Screening of ASFV targets and design of target crRNA
[0063] According to the gene sequence and CRISPR-Cas12a nucleic acid detection system, after repeated screening and testing of the CP530R, H240R, and MGF505-7R gene detection targets, multiple crRNAs for each detection target were obtained, and two crRNAs were designed for each detection target. The sequences of multiple crRNAs are shown in SEQ ID No: 1 to SEQ ID No: 6, see Table 1. Among them, SEQ ID No: 1 and SEQ ID No: 2 are for the CP530R gene, SEQ ID No: 3 and SEQ ID No: 4 are for the MGF505-7R gene, and SEQ ID No: 5 and SEQ ID No: 6 are for the H240R gene. The screening results are as follows Figure 2 shown.
[0064] Table 1
[0065]
[0066]
[0067] Preparation Example 2: Design and Screening of Constant Temperature Amplification Primers for Identification of CP530R, H240R, and MGF505-7R
[0068] For the detection targets of CP530R, H240R and MGF505-7R, two pairs of primers capable of specific amplification are designed for each. The sequences of the multiple primer pairs are shown in SEQ ID No:7 to SEQ ID No:18, as shown in Table 2. Among them, the first primer pair composed of SEQ ID No:7 and SEQ ID No:8, and the second primer pair composed of SEQ ID No:9 and SEQ ID No:10 are used to amplify the CP530R gene; the third primer pair composed of SEQ ID No:11 and SEQ ID No:12, and the fourth primer pair composed of SEQ ID No:13 and SEQ ID No:14 are used to amplify the MGF505-7R gene; the fifth primer pair composed of SEQ ID No:15 and SEQ ID No:16, and the sixth primer pair composed of SEQ ID No:17 and SEQ ID No:18 are used to amplify the H240R gene.
[0069] Table 2
[0070]
[0071]
[0072] Preparation Example 3: Preparation of positive standard plasmid
[0073] According to the sequences shown in SEQ ID No: 19 (CP530R), SEQ ID No: 20 (H240R) and SEQ ID No: 21 (MGF505-7R), artificially synthesized fragments of African swine fever virus CP530R, H240R and MGF505-7R genes were synthesized; the synthetic fragments were connected to the pUC57 cloning vector in a ratio of 1:1 to form a recombinant plasmid by means of recombinant DNA technology; the obtained recombinant plasmid was transformed into DH5α competent cells, the transformed competent cells were cultured, and after a single colony was grown, the single colony was picked out for amplification and then extracted to obtain a positive control plasmid, the concentration of the extracted plasmid was measured by an ultramicro spectrophotometer, and the copy number was calculated.
[0074] Example 1. Construction of ERA amplification system
[0075] ERA is used to perform a constant temperature amplification reaction on the nucleic acid of the African swine fever virus sample (i.e., the DNA template extracted from the sample to be tested, where the extraction of the DNA template can be performed in a manner well known to those skilled in the art, for example, a nucleic acid rapid release agent can be used to release the nucleic acid in the sample to be tested to obtain the DNA template), and the nucleic acid amplification system is shown in Table 3. The reaction solution is prepared according to the parameters in Table 3, and the prepared reaction solution is placed in a 42°C constant temperature metal bath or PCR instrument for reaction for 30 minutes, and the amplification product is taken out after the amplification is completed, and the amplified product is stored at 4°C for later use.
[0076] It should be noted that
[0077] Table 3
[0078] Isothermal amplification reaction system Volume (μL) Dissolving agent 20 Forward Primer 2.5 Reverse primer 2.5 DNA template 10 <![CDATA[ddH2O]]> 13 Activator 2
[0079] Example 2: Identification of ASFV-CP530R, H240R, MGF505-7R gene deletions based on CRISPR-Cas12a
[0080] 1. Synthesize single-stranded DNA fluorescent reporter probe
[0081] The single-stranded DNA fluorescent reporter probe can be constructed by labeling the FAM fluorescent group and the BHQ1 fluorescent quenching group at both ends of the single-stranded DNA gene sequence. The gene sequence of the reporter probe is: 5'-FAM-TTTTTTTT-BHQ1-3' (i.e., the first ssDNA reporter molecule), which is synthesized by Nanjing GeneWeizhi Biotechnology Co., Ltd.
[0082] 2. Fluorescence detection of CRISPR-Cas12a system
[0083] The gene amplification products of African swine fever virus CP530R, H240R, and MGF505-7R were detected using the CRISPR-Cas12a nucleic acid detection system established by the present invention, and the fluorescence detection system was prepared according to Table 4. The prepared reaction solution was added to a 96-well plate, and the fluorescence intensity was detected using a multifunctional microplate reader or a fluorescence quantitative PCR instrument, wherein the microplate reader was set to an excitation light wavelength of 495nm and an emission light wavelength of 520nm, and the fluorescence quantitative PCR instrument selected the FAM fluorescence channel. The reaction temperature was 37°C, and the fluorescence value was detected every 2 minutes for 30 minutes, and the fluorescence intensity increase in each target CRISPR detection reaction was observed.
[0084] Table 4
[0085] Cas12a / crRNA reaction system Volume (μL) Buffer 3 Enzymes 1 crRNA 2 Probe 6 DNA (i.e., the amplified product in Example 1) 10 <![CDATA[ddH2O]]> 8
[0086] 3. Determination of positive results
[0087] Compared with the negative control, the fluorescence intensity increased significantly at 30 minutes. After statistical analysis, the fluorescence intensity values of three repeated experiments were statistically different from those of the negative control.
[0088] Five possible test results are predicted:
[0089] ① If all three tubes are fluorescent, it means that the sample tested is infected with ASFV wild strain;
[0090] ② If the CP530R tube emits fluorescence, but the other two tubes do not, it means that the sample tested is the H240R and MGF505-7R double gene deletion vaccine strain;
[0091] ③ If one H240R tube does not emit fluorescence, but the other two tubes do, it means that the sample tested is the H240R-deficient vaccine strain;
[0092] ④ If one MGF505-7R tube does not emit fluorescence, but the other two tubes do, it means that the sample tested is the MGF505-7R-deficient vaccine strain;
[0093] ⑤ If there is no fluorescence in all three test tubes, it means that the test result is negative, that is, the tested sample is not infected with ASFV wild strain.
[0094] Example 3, ERA-Cas12a detection reaction system process and optimization
[0095] The ERA-Cas12a reaction system optimization process of the present invention is:
[0096] 2×10 4 The gene recombinant plasmid with a copy / μL concentration was used as a template. The experiments were carried out with a crRNA (pmol) / Cas12a (pmol) ratio of 1:1, 1.2:1, 1.4:1, 1.6:1, 1.8:1 and 2:1, respectively. The reaction system was 10 μL, including 100 nM of Cas12a protein, 100 nM of crRNA, 120 nM, 140 nM, 160 nM, 180 nM, 200 nM, 1 μM of FAM-BHQ1 single-stranded DNA probe (i.e., the first ssDNA reporter molecule), 1 μM, 1 × 2.1 NEBuffer, 1 μL of recombinant plasmid template, DEPC water supplemented to 10 μL, the reaction temperature was 37 ° C, the reaction time was 15 min, and the final fluorescence value generated by the reaction was measured by a fluorescence quantifier, and the optimized Cas12a protein / crRNA ratio was finally obtained to be 1:1.4.
[0097] Verification Example 1: Sensitivity Experiment
[0098] The ERA-Cas12a fluorescence detection process constructed based on Example 2 is as follows:
[0099] For the three genes CP530R, H240R and MGF505-7R of African swine fever virus, the ERA method was used for amplification. The detailed configuration of the ERA nucleic acid amplification kit and amplification system used is shown in Table 5. The specific steps of the amplification process are as follows:
[0100] (1) All primers used for ERA amplification were prepared at a working concentration of 10 μM using TE solution.
[0101] (2) Prepare the ERA amplification reaction system according to the following guidelines. After preparation, vortex thoroughly and centrifuge briefly to ensure uniform mixing.
[0102] (3) Add 2 μL of activator to the lid of each reaction tube, then carefully seal it and centrifuge briefly to promote uniform mixing of the activator and reaction mixture.
[0103] (4) Place the reaction tube in a 37°C water bath and incubate for 20 minutes.
[0104] (5) After the incubation is completed, remove the reaction tube for subsequent experimental steps.
[0105] Table 5
[0106] Components Volume / μL Dissolving agent 20 Forward Primer 2.5 Reverse primer 2.5 DNA 10 <![CDATA[H2O]]> 13 Activator 2 Total volume 50
[0107] The product obtained by the above ERA amplification is introduced into the Cas12a reaction system (as shown in Table 6), which includes LbCas12a protein, buffer, crRNA, ssDNA probe and deionized water (ddH2O). In order to verify the cutting activity of Cas12a, an experimental group and a negative control group are set for each amplified gene: crRNA and positive plasmid are added to the experimental group, and crRNA and DEPC-treated water are added to the negative control group. The necessary components are added to the PCR tube, and after ensuring uniform mixing, a real-time fluorescence quantitative PCR instrument is used to react at 37 ° C for 30 minutes. After the reaction is completed, a blue light gel imager is used to observe and record the fluorescence intensity.
[0108] Table 6
[0109] Components Volume / μL Cleavagebuffer 3 LbCas12a 1 crRNA 2 Fluorescent reporter probe 6 DNA 10 <![CDATA[ddH2O]]> 8 Total volume 30
[0110] 2×10 9 The CP530R, H240R and MGF505-7R positive standard recombinant plasmids with a concentration of copies / μL were each diluted 10-fold to 2×10 0 Copies / μL, 2×10 1 Copies / μL, 2×10 2 Copies / μL, 2×10 3 Copies / μL, 2×10 4Copies / μL, 2×10 5 Copies / μL, 2×10 6 Copies / μL; DEPC water was used as negative control. When the concentration of CP530R, H240R and MGF505-7R positive standard plasmids was as low as 10 copies, the test result was negative. Therefore, the minimum detectable number of CP530R, H240R and MGF505-7R positive standard recombinant plasmids was 10 copies.
[0111] The sensitivity was tested by the fluorescence detection method described in Example 2 and the colloidal gold test strip described in Example 3, and the results were as follows: Figure 3 and Figure 5 As shown. Among them, Figure 5 The markings here are Figure 3 Correspondingly, Figure 5 Bands 1-8 in A-5C are Figure 3 The concentrations of the positive standard plasmids in bands 1-8 in A-3C correspond one to one. Specifically, Figure 3 A- Figure 3 C corresponds to the sensitivity test results of CP530R, H240R and MGF505-7R, and the corresponding concentrations from left to right in each figure are 1×10 6 copies / μL, 1×10 5 copies / μL, 1×10 4 copies / μL, 1×10 3 copies / μL, 1×10 2 copies / μL, 1×10 1 copies / μL, 1×10 0 copies / μL and negative control; Figure 5 A- Figure 5 C corresponds to the sensitivity test results of CP530R, H240R and MGF505-7R, and the corresponding concentrations from left to right in each figure are 1×10 6 copies / μL, 1×10 5 copies / μL, 1×10 4 copies / μL, 1×10 3 copies / μL, 1×10 2 copies / μL, 1×10 1 copies / μL, 1×10 0 copies / μL and negative control.
[0112] Verification Example 2: Specificity Experiment
[0113] In addition, PRRSV, CFV, PEDV and TGEV were used for specific detection; the genomes of various porcine pathogens including PRV, PEDV, CSFV, PCV2 and PRRSV were used as templates for specific detection, and DEPC water was used as a negative control.
[0114] The specificity was verified by fluorescence detection method, and the results were as follows Figure 4 shown.
[0115] The CRISPR / Cas12a lateral flow (colloidal gold test strip) detection method was used to verify its specificity. The probe used was 5′-FAM-TTTATTT-Biotin-3′ (i.e., the second ssDNA reporter molecule). The results obtained were as follows Figure 6 shown. Specifically, Figure 4 A- Figure 4 C corresponds to the specific detection results of CP530R, H240R and MGF505-7R, and each figure corresponds from left to right: positive control, PRv-Bartha, PRV-Fa, PEDV, CSFV, PCV-2, PRRSV, negative control; Figure 6 A- Figure 6 C corresponds to the specific detection results of CP530R, H240R and MGF505-7R, and each figure corresponds from left to right: positive control, PRV-Bartha, PEDV, CSFV, PCV-2, PRRSV, and negative control.
[0116] pass Figure 4 and Figure 6 It can be seen that the scheme of the present invention can specifically detect ASFV for different genes and does not cross-react with other viruses. Based on the above detection, different strains of African swine fever virus can be further detected by identification.
[0117] Verification Example 3: Compliance test of the kit for detecting African swine fever virus nucleic acid using CRISPR-Cas12a fluorescence method
[0118] In order to determine the compliance of this application with the real-time fluorescence RT-PCR method recommended by WOAH, the applicant prepared 40 blind samples, which were tested by other uninformed testers using the two aforementioned methods. The evaluation results are shown in Table 7, which show that the compliance rate is 100%.
[0119] Among them, the specific operation of the real-time fluorescence RT-PCR method recommended by WOAH is as follows:
[0120] Directly use the primers and probes publicly provided and recorded in Chapter 2.8.1 African Swine Fever of the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals of the World Organization for Animal Health (WOAH) (specifically, upstream primer ASF-OIE-rPCRF: 5'-1627-CTGCTCATGGTATCAATCTTATCGA-1651-3'; downstream primer ASF-OIE-rPCRR: 5'-1857-GATACCACAAGATCRGCCGT-1876-3'; fluorescent probe ASF-OIE-Probe: 5'-1761-FAM-CCACGGGAGGAATACCAACCCAGTG-TAMRA-1785-3'), and operate according to the detection procedures and judgment criteria specified in the manual.
[0121] Table 7
[0122]
[0123] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0124] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
[0125] In addition, various embodiments of the present invention may be arbitrarily combined, and as long as they do not violate the concept of the present invention, they should also be regarded as the contents disclosed by the present invention.
Claims
1. A specific crRNA for identifying different types of ASFV based on CRISPR / Cas12a, characterized in that: The specific crRNA includes a first crRNA and a second crRNA; wherein, The first crRNA is shown in SEQ ID No: 1 and / or SEQ ID No: 2; The second crRNA is shown in one or more of SEQ ID No:3, SEQ ID No:4, SEQ ID No:5 and SEQ ID No:
6.
2. The specific crRNA according to claim 1, characterized in that The first crRNA is as described in SEQ ID No: 2; The second crRNA is shown in SEQ ID No:4 and / or SEQ ID No:
6.
3. A detection system for identifying different types of ASFV based on CRISPR / Cas12a, characterized in that: The detection system includes at least the specific crRNA as described in claim 1 or 2, a first isothermal amplification primer pair that matches the first crRNA for amplifying the template to be tested, a second isothermal amplification primer pair that matches the second crRNA for amplifying the template to be tested, and a ssDNA reporter system.
4. The detection system according to claim 3, characterized in that: The first isothermal amplification primer pair is selected from the first primer pair as shown in SEQ ID No: 7 and SEQ ID No: 8 and / or the second primer pair as shown in SEQ ID No: 9 and SEQ ID No: 10, and the second isothermal amplification primer pair is selected from the third primer pair as shown in SEQ ID No: 11 and SEQ ID No: 12, the fourth primer pair as shown in SEQ ID No: 13 and SEQ ID No: 14, the fifth primer pair as shown in SEQ ID No: 15 and SEQ ID No: 16, and the sixth primer pair as shown in SEQ ID No: 17 and SEQ ID No:
18. Preferably, when containing the second crRNA as shown in SEQ ID No: 3 and / or SEQ ID No: 4, a third primer pair and / or a fourth primer pair is used; When containing the second crRNA as shown in SEQ ID No: 5 and / or SEQ ID No: 6, the fifth primer pair and / or the sixth primer pair are used; More preferably, the first isothermal amplification primer pair is selected from the second primer pair, and the second isothermal amplification primer pair is selected from the fourth primer pair and / or the sixth primer pair.
5. The detection system according to claim 3 or 4, characterized in that: The ssDNA reporter system includes a first ssDNA reporter molecule for fluorescence detection, and / or a second ssDNA reporter molecule for colloidal gold detection; Preferably, the nucleotide sequence of the first ssDNA reporter molecule is: 5'-TTTTTTTT-3', and the nucleotide sequence of the second ssDNA reporter molecule is: 5'-TTTATTT-3'.
6. The detection system according to claim 5, characterized in that The 5' end of the first ssDNA reporter molecule is modified with a FAM group, and the 3' end is modified with a BHQ1 group; The 5' end of the second ssDNA reporter molecule is modified with a FAM group, and the 3' end is modified with a Biotin group.
7. The detection system according to claim 3 or 4, characterized in that: The detection system also includes a solvent and an activator required for the ERA process, and a Cas12a protein required for the CRISPR / Cas12a system; and, Relative to 1 pmol of Cas12a protein, the content of crRNA is 1-2 pmol; Preferably, the reaction conditions of the ERA process are: reaction at 37° C. for 20-30 min.
8. An application of a specific crRNA according to claim 1 or 2, or a detection system according to any one of claims 3-7 in the preparation of different types of ASFV identification detection kits.
9. A method for identifying different types of ASFV for non-disease diagnosis purposes, characterized in that: The identification method adopts the detection system described in any one of claims 3 to 7; Preferably, the identification method is used to identify at least two of the ASFV wild strain, the H240R deletion vaccine strain and the MGF505-7R deletion vaccine strain.
10. The identification method according to claim 9, characterized in that: The identification method comprises: S100, releasing the nucleic acid in the sample to be tested to obtain a template to be tested, and using multiple sets of isothermal amplification primers to specifically amplify each template to be tested to obtain multiple corresponding amplification products; S200, activating the non-specific single-stranded DNA cleavage activity of the Cas12a enzyme by binding crRNA to the specific gene sequence in the amplified product in step S100; S300, based on the ssDNA reporter system, determining the plant type of the template to be tested by detecting the reporter signal; Preferably, when the ssDNA reporter system in step S300 uses the first ssDNA reporter molecule, the detection conditions are: using excitation light with a wavelength of 492 nm and detecting the radiated fluorescence intensity at a wavelength of 522 nm.
Citation Information
Patent Citations
Double fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection reagent for African swine fever viruses and porcine reproductive and respiratory syndrome viruses and preparation method and application thereof
CN104745729A
Triple fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection reagent for African swine fever viruses, swine fever viruses and respiratory syndrome viruses and preparation method and application thereof
CN104745731A
Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof
CN113543801A
Nucleic acid single-channel multiple rapid amplification and multi-point detection method
CN113999895A
Recombinant attenuated strain with deletion of African swine fever virus gene as well as preparation method and application of recombinant attenuated strain
CN115717129A
Cited By
Portable African swine fever detection method based on ERA-CRISPR / Cas12a technology
CN120775959A
